Prostate Cancer: 4th Edition

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 255

Special Issue Editors


E-Mail Website
Guest Editor
1. Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), Institute for Innovation, Capacity Building and Sustainability of Agri-Food Production (Inov4Agro), University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal
2. Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal
Interests: animal models; in vivo studies; natural compounds
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Zootechnics, School of Sciences and Technology, University of Évora, Évora, Portugal
2. Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), Vila Real, Portugal
Interests: veterinary medicine; experimental animal models; anti-inflammatory drugs; physical exercise; tumor angiogenesis; lymphangiogenesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are grateful to the researchers who contributed to the first, second and third volumes of this Special Issue:

Prostate Cancer: https://www.mdpi.com/journal/life/special_issues/pros_can

Prostate Cancer: 2nd Edition: https://www.mdpi.com/journal/life/special_issues/Z5E9V92OYG

Prostate Cancer: 3rd Edition: https://www.mdpi.com/journal/life/special_issues/3R8S8NX46G

We are pleased to announce the upcoming publication of our Special Issue, entitled “Prostate Cancer: 4th Edition".

The prostate is the largest accessory gland of the male reproductive tract. Together with seminal vesicles and bulbourethral glands, the prostate is responsible for the production of an alkaline fluid that forms part of the seminal fluid. The prostates of men over 40 years of age are commonly affected by several pathologies, such as benign prostate hyperplasia and cancer.

Prostate cancer is one of the most frequently occurring cancers among the male population worldwide. According to the World Health Organization (WHO), the year 2020 saw prostate cancer affect approximately 1.41 million men and be responsible for the deaths of 375,304 of them. Prostate cancer development is associated with several risk factors, including older age, African ancestry, a family history of the disease, an increased body mass index, and obesity. The risk of prostate cancer development may be reduced through the consumption of a healthy diet full of fruits and vegetables, physical exercise, and maintenance of a healthy weight.

Despite several approaches being available for prostate cancer treatment, the number of prostate cancer deaths is continuously increasing. This emphasizes the need to search for new methods for precocious diagnosis and more effective treatment. Animal models, including rodents, have greatly contributed to the study of biopathology and the prevention and treatment of prostate cancer.

This Special Issue, entitled “Prostate Cancer: 4th Edition”, aims to publish original research works and reviews concerning the diagnosis, treatment, and prognosis of prostate cancer, highlighting new advances in this field.

Prof. Dr. Paula Oliveira
Dr. Ana Faustino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • incidence
  • mortality
  • diagnosis
  • histopathology
  • imaging
  • treatment
  • prognosis
  • case report
  • animals
  • humans
  • modeling

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 786 KiB  
Communication
Local Therapy Can Enhance the Prognosis of Certain Patients with Pathologically Diagnosed Neuroendocrine Prostate Carcinoma
by Shoichi Kimura, Naoki Terada, Shinnya Soumiya, Takayuki Goto, Hiromitsu Negoro, Shoichiro Mukai, Osamu Ogawa, Shusuke Akamatsu, Takashi Kobayashi, Atsuro Sawada and Toshiyuki Kamoto
Life 2025, 15(5), 797; https://doi.org/10.3390/life15050797 - 17 May 2025
Viewed by 126
Abstract
Neuroendocrine prostate cancer (NEPC) has a poor prognosis. We performed a retrospective analysis of the factors contributing to survival in patients with histologically diagnosed NEPC. Patients pathologically diagnosed with NEPC between 2007 and 2018 were retrospectively analyzed. Overall survival (OS) from the time [...] Read more.
Neuroendocrine prostate cancer (NEPC) has a poor prognosis. We performed a retrospective analysis of the factors contributing to survival in patients with histologically diagnosed NEPC. Patients pathologically diagnosed with NEPC between 2007 and 2018 were retrospectively analyzed. Overall survival (OS) from the time of the initial prostate cancer diagnosis was evaluated using the Kaplan–Meier method. Cox proportional hazards analyses were performed to evaluate the association of OS with variables including the presence of metastasis, receipt of local therapy, and disease classification (primary NEPC [p-NEPC] or treatment-related NEPC [t-NEPC]). Among 32 patients (p-NEPC, 22; t-NEPC, 10), distant metastases were identified in 25 (78%) patients, and local therapies including radical prostatectomy and local radiotherapy were provided to 21 (66%) patients. In the univariate Cox proportional hazard analyses, patients who received local therapy had a significantly lower risk of death than those who did not receive local therapy (hazard ratio = 0.284, 95% confidence interval = 0.109–0.738, p = 0.01). OS was significantly longer for patients receiving local therapy than for those who did not receive local therapy (36 months vs. 13 months, p = 0.0058). Our findings suggest the potential benefit of local therapy in the treatment of NEPC. Full article
(This article belongs to the Special Issue Prostate Cancer: 4th Edition)
Show Figures

Figure 1

Back to TopTop